NEW YORK, January 24, 2017 /PRNewswire/ --
On Monday, January 23, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Six out of nine sectors ended Monday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, Stock-Callers.com assessed the following Medical Laboratories & Research equities this morning: Quintiles IMS Holdings Inc. (NYSE: Q), OpGen Inc. (NASDAQ: OPGN), Novadaq Technologies Inc. (NASDAQ: NVDQ), and Biocept Inc. (NASDAQ: BIOC). Download the free research reports on these stocks today:
Durham, North Carolina-based Quintiles IMS Holdings Inc.'s stock finished Monday's session 0.33% lower at $75.85 with a total volume of 952,225 shares traded. Over the last three months and the previous one year, Quintiles IMS Holdings' shares have advanced 1.92% and 19.24%, respectively. The Company's shares are trading above its 200-day moving average by 3.25%. Shares of Quintiles IMS Holdings, which provides biopharmaceutical development services and commercial outsourcing services in the Americas, Europe, Africa, and the Asia/Pacific, are trading at a PE ratio of 23.27. The stock has a Relative Strength Index (RSI) of 41.49. See our free and comprehensive research report on Q at:
On Monday, shares in Gaithersburg, Maryland headquartered OpGen Inc. ended the session flat at $1.18 with a total volume of 243,334 shares traded. OpGen's shares have advanced 4.43% in the past one month. The stock is trading 0.94% above its 50-day moving average. Moreover, shares of the Company, which engages in developing and deploying precision medicine tools to combat infectious disease in global healthcare settings, have an RSI of 46.16. OPGN free research report PDF is just a click away at:
On Monday, shares in Mississauga, Canada headquartered Novadaq Technologies Inc. recorded a trading volume of 350,677 shares. The stock ended the day 1.09% higher at $6.47. The Company is trading below its 50-day and 200-day moving averages by 15.68% and 35.01%, respectively. Furthermore, shares of Novadaq Technologies, which develops, manufactures, and markets fluorescence imaging products for use by surgeons in the operating room and other clinical settings in the US and internationally, have an RSI of 37.59.
On January 11th, 2017, research firm Wedbush reiterated its 'Outperform' rating on the Company's stock with a decrease of the target price from $17 a share to $11 a share. Sign up for your complimentary report on NVDQ at:
San Diego, California headquartered Biocept Inc.'s stock declined 7.74%, to close the day at $1.43. The stock recorded a trading volume of 1.15 million shares. Biocept's shares have surged 72.27% in the last one month and 49.61% in the previous three months. Furthermore, the stock has advanced 2.88% in the past one year. The Company's shares are trading 39.60% and 66.83% above its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample, have an RSI of 52.56. Register for free on Stock-Callers.com and download the latest research report on BIOC at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA